Staneva-Stoytcheva D, Raynova L L, Bogoslovova T, Ivanov D, Georgieva A
Acta Physiol Pharmacol Bulg. 1985;11(2):35-43.
An experimental model of the "withdrawal syndrome" in chronic clonidine treatment is reproduced in spontaneously hypertensive rats (SHR). Medication is withdrawn abruptly after daily oral administration of 100 micrograms/kg clonidine for 12 days or after it has been received with the drinking water in a dose of approximately 250 micrograms/kg daily for 14 days. In the course of the treatment, as well as on the 24th and 48th hour after withdrawal, studies are carried out of the changes in the arterial pressure, heart rate, vascular resistance, the contractions of electrically stimulated m.anococcygeus and vas deferens, as well as some biochemical parameters (noradrenaline content in the brain and myocardium, the level of glucose and free fatty acids in the blood, the activity of phosphorylase "a" in the myocardium). In the course of clonidine treatment there is potentiation of the peripheral noradrenaline effects on the arterial pressure and vascular resistance, increasing hyperglycaemia, reduced noradrenaline content in the brain and myocardium, as well as potentiation of the inhibitory effect of clonidine on the contractions of electrically stimulated m.anococcygeus, as well as potentiation of the isoprenaline responses on the arterial pressure. The isoprenaline effects on electrically stimulated vas deferens, as well as the activity of the stimulated phosphorylase "a", decrease. No sharp increase in the arterial blood pressure was observed upon withdrawal of the clonidine treatment. The reactivity of the peripheral pre- and postsynaptic alpha-adrenergic receptors is intensified (the effects of noradrenaline on the arterial pressure and vascular resistance become even stronger, the noradrenaline content in the brain and myocardium and hyperglycaemia increase, and there is potentiation of the inhibitory effect of clonidine on electrically stimulated m.anococcygeus.(ABSTRACT TRUNCATED AT 250 WORDS)
在自发性高血压大鼠(SHR)中复制了慢性可乐定治疗的“戒断综合征”实验模型。在每日口服100微克/千克可乐定12天或每日以约250微克/千克的剂量通过饮用水给药14天后,突然停药。在治疗过程中以及停药后第24小时和48小时,对动脉血压、心率、血管阻力、电刺激尾骨肌和输精管的收缩变化以及一些生化参数(脑和心肌中的去甲肾上腺素含量、血液中的葡萄糖和游离脂肪酸水平、心肌中磷酸化酶“a”的活性)进行研究。在可乐定治疗过程中,外周去甲肾上腺素对动脉血压和血管阻力的作用增强,高血糖增加,脑和心肌中的去甲肾上腺素含量降低,可乐定对电刺激尾骨肌收缩的抑制作用增强,以及异丙肾上腺素对动脉血压的反应增强。异丙肾上腺素对电刺激输精管的作用以及受刺激的磷酸化酶“a”的活性降低。停药后未观察到动脉血压急剧升高。外周突触前和突触后α-肾上腺素能受体的反应性增强(去甲肾上腺素对动脉血压和血管阻力的作用变得更强,脑和心肌中的去甲肾上腺素含量以及高血糖增加,可乐定对电刺激尾骨肌的抑制作用增强)。(摘要截短至250字)